Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ATR_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATR_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATR_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ATR_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070638 | Thyroid | PTC | regulation of sister chromatid cohesion | 13/5968 | 21/18723 | 4.41e-03 | 2.08e-02 | 13 |
GO:00323928 | Thyroid | PTC | DNA geometric change | 41/5968 | 90/18723 | 4.47e-03 | 2.11e-02 | 41 |
GO:000706410 | Thyroid | PTC | mitotic sister chromatid cohesion | 16/5968 | 28/18723 | 4.99e-03 | 2.31e-02 | 16 |
GO:00031705 | Thyroid | PTC | heart valve development | 31/5968 | 65/18723 | 5.54e-03 | 2.52e-02 | 31 |
GO:004654612 | Thyroid | PTC | development of primary male sexual characteristics | 60/5968 | 142/18723 | 5.79e-03 | 2.61e-02 | 60 |
GO:00352648 | Thyroid | PTC | multicellular organism growth | 56/5968 | 132/18723 | 6.79e-03 | 2.92e-02 | 56 |
GO:000858412 | Thyroid | PTC | male gonad development | 59/5968 | 141/18723 | 7.88e-03 | 3.33e-02 | 59 |
GO:00456697 | Thyroid | PTC | positive regulation of osteoblast differentiation | 32/5968 | 69/18723 | 8.16e-03 | 3.44e-02 | 32 |
GO:00309007 | Thyroid | PTC | forebrain development | 143/5968 | 379/18723 | 8.47e-03 | 3.56e-02 | 143 |
GO:00070629 | Thyroid | PTC | sister chromatid cohesion | 29/5968 | 62/18723 | 9.96e-03 | 4.07e-02 | 29 |
GO:00600083 | Thyroid | PTC | Sertoli cell differentiation | 11/5968 | 18/18723 | 1.00e-02 | 4.07e-02 | 11 |
GO:00459434 | Thyroid | PTC | positive regulation of transcription by RNA polymerase I | 13/5968 | 23/18723 | 1.25e-02 | 4.88e-02 | 13 |
GO:1903362210 | Thyroid | goiters | regulation of cellular protein catabolic process | 22/497 | 255/18723 | 1.35e-06 | 7.39e-05 | 22 |
GO:0042176210 | Thyroid | goiters | regulation of protein catabolic process | 26/497 | 391/18723 | 1.84e-05 | 7.00e-04 | 26 |
GO:000150324 | Thyroid | goiters | ossification | 25/497 | 408/18723 | 1.00e-04 | 3.16e-03 | 25 |
GO:000164924 | Thyroid | goiters | osteoblast differentiation | 17/497 | 229/18723 | 1.39e-04 | 4.10e-03 | 17 |
GO:190336327 | Thyroid | goiters | negative regulation of cellular protein catabolic process | 9/497 | 75/18723 | 1.61e-04 | 4.58e-03 | 9 |
GO:004217727 | Thyroid | goiters | negative regulation of protein catabolic process | 11/497 | 121/18723 | 3.81e-04 | 9.50e-03 | 11 |
GO:0031330210 | Thyroid | goiters | negative regulation of cellular catabolic process | 17/497 | 262/18723 | 6.68e-04 | 1.55e-02 | 17 |
GO:004566714 | Thyroid | goiters | regulation of osteoblast differentiation | 11/497 | 132/18723 | 7.96e-04 | 1.74e-02 | 11 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0421810 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0517016 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa041106 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa0421815 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa05166110 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0517017 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0411013 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa051661 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa051702 | Colorectum | SER | Human immunodeficiency virus 1 infection | 58/1580 | 212/8465 | 1.08e-03 | 8.56e-03 | 6.21e-03 | 58 |
hsa051703 | Colorectum | SER | Human immunodeficiency virus 1 infection | 58/1580 | 212/8465 | 1.08e-03 | 8.56e-03 | 6.21e-03 | 58 |
hsa051704 | Colorectum | MSS | Human immunodeficiency virus 1 infection | 69/1875 | 212/8465 | 2.66e-04 | 1.98e-03 | 1.21e-03 | 69 |
hsa042182 | Colorectum | MSS | Cellular senescence | 52/1875 | 156/8465 | 7.87e-04 | 5.07e-03 | 3.11e-03 | 52 |
hsa051662 | Colorectum | MSS | Human T-cell leukemia virus 1 infection | 68/1875 | 222/8465 | 1.84e-03 | 9.61e-03 | 5.89e-03 | 68 |
hsa051705 | Colorectum | MSS | Human immunodeficiency virus 1 infection | 69/1875 | 212/8465 | 2.66e-04 | 1.98e-03 | 1.21e-03 | 69 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATR | SNV | Missense_Mutation | novel | c.6307G>A | p.Glu2103Lys | p.E2103K | Q13535 | protein_coding | deleterious(0.01) | benign(0.075) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ATR | SNV | Missense_Mutation | novel | c.5518G>C | p.Glu1840Gln | p.E1840Q | Q13535 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ATR | SNV | Missense_Mutation | rs762196224 | c.7724N>T | p.Ala2575Val | p.A2575V | Q13535 | protein_coding | tolerated(0.07) | benign(0.304) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ATR | SNV | Missense_Mutation | | c.6400G>T | p.Ala2134Ser | p.A2134S | Q13535 | protein_coding | tolerated(0.12) | benign(0.021) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATR | SNV | Missense_Mutation | | c.2246N>G | p.Ser749Cys | p.S749C | Q13535 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ATR | SNV | Missense_Mutation | rs746049210 | c.7219N>T | p.Arg2407Cys | p.R2407C | Q13535 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATR | SNV | Missense_Mutation | rs780802796 | c.3548N>A | p.Arg1183Gln | p.R1183Q | Q13535 | protein_coding | tolerated(0.11) | possibly_damaging(0.688) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATR | SNV | Missense_Mutation | rs369309229 | c.6196N>T | p.Arg2066Trp | p.R2066W | Q13535 | protein_coding | tolerated(0.08) | probably_damaging(0.939) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ATR | SNV | Missense_Mutation | | c.226N>C | p.Met76Leu | p.M76L | Q13535 | protein_coding | tolerated_low_confidence(0.05) | benign(0.01) | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATR | SNV | Missense_Mutation | novel | c.4627N>C | p.Glu1543Gln | p.E1543Q | Q13535 | protein_coding | tolerated(0.11) | possibly_damaging(0.743) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | | M4344 | | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | | E7449 | 2X-121 | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 384403635 | | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | CHEMBL3545178 | CERALASERTIB | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 328083492 | CERALASERTIB | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 249565722 | | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | | CISPLATIN | CISPLATIN | 12894503 |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 249565633 | DACTOLISIB | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | | BMN673 | | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 252166686 | | |